Federated Hermes Inc. acquired a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 133,189 shares of the biotechnology company’s stock, valued at approximately $1,253,000. Federated Hermes Inc. owned approximately 0.63% […]
Clearstead Advisors LLC bought a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,064 shares of the biotechnology company’s stock, valued at approximately $57,000. Other institutional investors and hedge funds have […]
Virtus ETF Advisers LLC lowered its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 11.5% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 12,784 shares of the biotechnology company’s stock after selling 1,654 shares during the period. Virtus ETF Advisers LLC’s holdings in Enanta Pharmaceuticals were worth $143,000 […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) CFO Paul J. Mellett sold 2,412 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $9.63, for a total value of $23,227.56. Following the sale, the chief financial officer now directly owns 93,549 shares in […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) VP Brendan Luu sold 2,125 shares of the stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $9.63, for a total value of $20,463.75. Following the sale, the vice president now directly owns 36,736 shares in the […]